StockData

Alnylam Pharmaceuticals vs Insmed

ALNY and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and INSM compare

Insmed is the larger company, worth 1.3 times as much as Alnylam Pharmaceuticals ($26.7B against $21.0B).

Insmed grew revenue faster over the last twelve months (240% versus 56.2% for Alnylam Pharmaceuticals).

Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with −39.9% at Insmed.

Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYINSM
Size and price
Market cap$21.0B$26.7B
Share price$156.50$121.86
Change, 1 year−65.2%−36.9%
Change, 5 years−17.0%321%
Beta (5Y)0.920.84
Employees2,5001,664
StockData Score
Total score10 (better)8
Valuation score3 (better)0
Growth score23 (better)
Performance score3 (better)2
Health score23 (better)
Dividend score00
Valuation
P/E8.1×–
P/S4.2× (better)17.6×
P/B5.8× (better)36.8×
EV/EBITDA16.8×–
P/FCF26.0×–
FCF yield3.8% (better)−2.3%
Fair value$296.91$61.10
Margin of safety47.3% (better)−99.5%
Growth
Revenue growth (TTM)56.2%240% (better)
Revenue growth, 5Y average49.8% (better)29.8%
Net income growth (TTM)2137%–
EPS growth (TTM)2308%–
Profitability
Gross margin77.4%84.4% (better)
Operating margin19.5% (better)−37.1%
Net margin52.8% (better)−39.9%
FCF margin16.1% (better)−41.3%
Return on equity127% (better)−72.5%
Financial health
Debt / equity–0.76
Interest coverage3.2× (better)−6.9×
Current ratio2.482.86 (better)
Altman Z-score3.627.42 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.7%102%
Held by insiders0.49%0.89%
Insider net buying, 12 months−$26.3M (better)−$133M
Superinvestors holding–1
Short interest, % of float4.1%6.5%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.